Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92


Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.

Bukhari A, El Chaer F, Koka R, Singh Z, Hutnick E, Ruehle K, Lee ST, Kocoglu MH, Shanholtz C, Badros A, Hardy N, Yared J, Rapoport AP, Dahiya S.

Am J Hematol. 2019 Oct;94(10):E273-E275. doi: 10.1002/ajh.25591. Epub 2019 Aug 13. No abstract available.


Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.

Stadtmauer EA, Faitg TH, Lowther DE, Badros AZ, Chagin K, Dengel K, Iyengar M, Melchiori L, Navenot JM, Norry E, Trivedi T, Wang R, Binder GK, Amado R, Rapoport AP.

Blood Adv. 2019 Jul 9;3(13):2022-2034. doi: 10.1182/bloodadvances.2019000194.


Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.

Duong VH, Holtzman NG, Koka R, Singh ZN, Zou Y, Emadi A, Rapoport AP, Kocoglu MH, Baer MR, Badros AZ.

Leuk Lymphoma. 2019 Jul 8:1-4. doi: 10.1080/10428194.2019.1633639. [Epub ahead of print] No abstract available.


Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.

Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, Lazaryan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim S, Locke FL, Robinson TJ.

Int J Radiat Oncol Biol Phys. 2019 Jun 5. pii: S0360-3016(19)30819-3. doi: 10.1016/j.ijrobp.2019.05.065. [Epub ahead of print]


Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

Badros AZ, Ma N, Rapoport AP, Lederer E, Lesokhin AM.

Blood Adv. 2019 Jun 11;3(11):1658-1660. doi: 10.1182/bloodadvances.2019000191. No abstract available.


Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.

Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, Ruehle K, Kocoglu MH, Badros A, Hardy N, Yared J, Rapoport AP, Fontaine M, Emadi A, El Chaer F, Dahiya S.

Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7. No abstract available.


Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.

Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM.

Cancer. 2019 Jun 1;125(11):1830-1836. doi: 10.1002/cncr.31877. Epub 2019 Feb 1.


Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival.

Hari P, Reece DE, Randhawa J, Flomenberg N, Howard DS, Badros AZ, Rapoport AP, Meisenberg BR, Filicko-Ohara J, Phillips GL, Vesole DH.

Bone Marrow Transplant. 2019 Feb;54(2):293-299. doi: 10.1038/s41409-018-0261-y. Epub 2018 Jun 15.


Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL.

El Chaer F, Holtzman N, Binder E, Porter NC, Singh ZN, Koka M, Rapoport AP, Emadi A.

Bone Marrow Transplant. 2017 Nov;52(11):1583-1584. doi: 10.1038/bmt.2017.191. Epub 2017 Sep 11. No abstract available.


Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z.

Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1.


Lenalidomide-induced eosinophilic pneumonia.

Toma A, Rapoport AP, Burke A, Sachdeva A.

Respirol Case Rep. 2017 Apr 25;5(4):e00233. doi: 10.1002/rcr2.233. eCollection 2017 Jul.


Genomics trumps clinical criteria in BMT? Nyet!

Holtzman NG, Rapoport AP.

Blood. 2017 Apr 27;129(17):2335-2336. doi: 10.1182/blood-2017-03-771477. No abstract available.


Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, Yanovich S, Sausville EA, Ujjani C, Ruehle K, Goecke C, Landau M, Rapoport AP.

Bone Marrow Transplant. 2016 Jun;51(6):850-2. doi: 10.1038/bmt.2015.346. Epub 2016 Feb 1. No abstract available.


Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma.

Simpson HM, Khan RZ, Song C, Sharma D, Sadashivaiah K, Furusawa A, Liu X, Nagaraj S, Sengamalay N, Sadzewicz L, Tallon LJ, Chen QC, Livak F, Rapoport AP, Kimball A, Banerjee A.

PLoS One. 2015 Nov 4;10(11):e0141906. doi: 10.1371/journal.pone.0141906. eCollection 2015.


Myeloma escape from immunity: an "inside" job.

Rapoport AP.

Blood. 2015 Sep 17;126(12):1401-3. doi: 10.1182/blood-2015-07-659490.


NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.


TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.

Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E.

Cancer Res. 2015 May 15;75(10):1959-1971. doi: 10.1158/0008-5472.CAN-14-2467. Epub 2015 Mar 20.


Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.

Ofran Y, Lazarus HM, Rapoport AP, Rowe JM.

Bone Marrow Transplant. 2015 Mar;50(3):324-33. doi: 10.1038/bmt.2014.270. Epub 2015 Jan 12. Review.


Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.

Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, Rapoport AP, Yanovich S, Sausville EA, Baer MR, Badros AZ.

Cancer. 2015 Apr 1;121(7):1064-70. doi: 10.1002/cncr.29160. Epub 2014 Dec 2.


Survival analysis with functional covariates for partial follow-up studies.

Fang HB, Wu TT, Rapoport AP, Tan M.

Stat Methods Med Res. 2016 Dec;25(6):2405-2419. Epub 2014 Feb 24.


Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH.

Clin Cancer Res. 2014 Mar 1;20(5):1355-65. doi: 10.1158/1078-0432.CCR-13-2817. Epub 2014 Feb 11.


Splenectomy as a measure to treat prolonged post-transplant cytopenia associated with hypersplenism.

Brauer DL, Rapoport AP, Yanovich S, Akpek G.

Bone Marrow Transplant. 2014 May;49(5):717-9. doi: 10.1038/bmt.2013.238. Epub 2014 Jan 20. No abstract available.


Donating used CARs.

Rapoport AP.

Blood. 2013 Dec 12;122(25):4007-9. doi: 10.1182/blood-2013-10-528984.


Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies.

Bhatnagar B, Rapoport AP, Fang HB, Ilyas C, Marangoz D, Akbulut V, Ruehle K, Badros A, Yanovich S, Akpek G.

Ann Hematol. 2014 Apr;93(4):653-60. doi: 10.1007/s00277-013-1908-9. Epub 2013 Oct 6.


Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK.

Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.


Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH.

Blood. 2013 Aug 8;122(6):863-71. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14.


c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas.

Hu F, Gartenhaus RB, Zhao XF, Fang HB, Minkove S, Poss DE, Rapoport AP.

Leuk Res. 2013 Apr;37(4):447-54. doi: 10.1016/j.leukres.2012.11.010. Epub 2012 Dec 10.


Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.

Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE, Rassool FV.

Oncogene. 2013 Apr 4;32(14):1784-93. doi: 10.1038/onc.2012.203. Epub 2012 May 28.


Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease.

Brauer DL, Edelman B, Rapoport AP, Hess JR, Akpek G.

Transfusion. 2012 Nov;52(11):2432-5. doi: 10.1111/j.1537-2995.2012.03608.x. Epub 2012 Mar 21.


Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.

Singh SN, Cao Q, Gojo I, Rapoport AP, Akpek G.

Bone Marrow Transplant. 2012 Jul;47(7):1008-9. doi: 10.1038/bmt.2011.210. Epub 2011 Nov 14. No abstract available.


Cellular therapy with sequential unmanipulated donor lymphocyte infusions in drug-resistant cytomegalovirus (CMV) encephalitis.

Akpek G, Mikulski M, Kleinberg M, Badros A, Yanovich S, Rapoport AP.

Blood. 2011 May 26;117(21):5772-4. doi: 10.1182/blood-2011-02-334060. No abstract available.


Granulomatous amebic encephalitis: an under-recognized cause of infectious mortality after hematopoietic stem cell transplantation.

Akpek G, Uslu A, Huebner T, Taner A, Rapoport AP, Gojo I, Akpolat YT, Ioffe O, Kleinberg M, Baer MR.

Transpl Infect Dis. 2011 Aug;13(4):366-73. doi: 10.1111/j.1399-3062.2011.00612.x. Epub 2011 Feb 21.


Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide.

Danchaivijitr P, Yared J, Rapoport AP.

Am J Hematol. 2011 Mar;86(3):331-2. doi: 10.1002/ajh.21950. Epub 2011 Jan 26. No abstract available.


Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH.

Blood. 2011 Jan 20;117(3):788-97. doi: 10.1182/blood-2010-08-299396. Epub 2010 Oct 28.


Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso EA, Levine BL, Vonderheide RH, Jawad AF, June CH, Sullivan KE.

Blood. 2011 Jan 6;117(1):63-71. doi: 10.1182/blood-2010-07-296822. Epub 2010 Sep 23.


PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.

Hu F, Gartenhaus RB, Eichberg D, Liu Z, Fang HB, Rapoport AP.

Oncogene. 2010 Oct 7;29(40):5464-74. doi: 10.1038/onc.2010.275. Epub 2010 Jul 12.


Primary gastric T cell lymphoma mimicking marginal zone B cell lymphoma of mucosa-associated lymphoid tissue.

Holanda D, Zhao MY, Rapoport AP, Garofalo M, Chen Q, Zhao XF.

J Hematop. 2008 Jul;1(1):29-35. doi: 10.1007/s12308-008-0006-8. Epub 2008 May 20.


Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.

Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, Janofsky S, Yager K, Veloso E, Zheng Z, Milliron T, Westphal S, Cotte J, Huynh H, Cannon A, Yanovich S, Akpek G, Tan M, Virts K, Ruehle K, Harris C, Philip S, Vonderheide RH, Levine BL, June CH.

Clin Cancer Res. 2009 Jul 1;15(13):4499-507. doi: 10.1158/1078-0432.CCR-09-0418. Epub 2009 Jun 9.


Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.

Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF.

Clin Cancer Res. 2009 Mar 1;15(5):1708-20. doi: 10.1158/1078-0432.CCR-08-1543. Epub 2009 Feb 17.


Detection of CD4(+) T-cell antibodies in a patient with idiopathic CD4 T lymphocytopenia and cryptococcal meningitis.

Salit RB, Hankey KG, Yi R, Rapoport AP, Mann DL.

Br J Haematol. 2007 Oct;139(1):133-7.


Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.


Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53.

Nandi AK, Ford T, Fleksher D, Neuman B, Rapoport AP.

Biochem Biophys Res Commun. 2007 Jun 22;358(1):181-8. Epub 2007 Apr 30.


Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma.

Chumsri S, Tummala MK, Khna AM, Zhao XF, Rapoport AP.

Leuk Lymphoma. 2007 Mar;48(3):616-8. No abstract available.


Large cell lymphoma presenting as a flare of colitis in a patient with common variable immune deficiency.

Dunnigan M, Yfantis H, Rapoport AP, Hosseinzadeh K, Gocke CD, Cross RK.

Dig Dis Sci. 2007 Mar;52(3):830-4. No abstract available.


Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B.

Clin Lymphoma Myeloma. 2006 Nov;7(3):210-6.


Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study.

Buadi FK, Heyman MR, Gocke CD, Rapoport AP, Hakimian R, Bartlett ST, Sarkodee-Adoo C.

Am J Hematol. 2007 Mar;82(3):208-14.


REL-positive double minute chromosomes in follicular lymphoma.

Reader JC, Zhao XF, Butler MS, Rapoport AP, Ning Y.

Leukemia. 2006 Sep;20(9):1624-6. Epub 2006 Jun 15. No abstract available.


Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come.

Rapoport AP.

Bone Marrow Transplant. 2006 Feb;37(3):239-47. Review.


Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.

Gojo I, Meisenberg B, Guo C, Fassas A, Murthy A, Fenton R, Takebe N, Heyman M, Philips GL, Cottler-Fox M, Sarkodee-Adoo C, Ruehle K, French T, Tan M, Tricot G, Rapoport AP.

Bone Marrow Transplant. 2006 Jan;37(1):65-72.


Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, Veloso E, Zheng Z, Westphal S, Mair R, Chi N, Ratterree B, Pochran MF, Natt S, Hinkle J, Sickles C, Sohal A, Ruehle K, Lynch C, Zhang L, Porter DL, Luger S, Guo C, Fang HB, Blackwelder W, Hankey K, Mann D, Edelman R, Frasch C, Levine BL, Cross A, June CH.

Nat Med. 2005 Nov;11(11):1230-7. Epub 2005 Oct 16.


Supplemental Content

Loading ...
Support Center